- Home
- Healthcare professionals
- ACE Technology Guidances
- Drug Guidance
Drug Guidance
View all drug guidances and its details here.
159 articles
1 April 2025
Dutasteride, tamsulosin, alfuzosin and dutasteride/tamsulosin combination for treating benign prostatic hyperplasia
Condition
Urological
Withdrawn
17 February 2025
Axicabtagene ciloleucel for relapsed or refractory large B-cell lymphoma after two or more lines of systemic therapy
Condition
Cancer
Blood and Immune System
Drug guidance
17 February 2025
Axicabtagene ciloleucel for second-line relapsed or refractory large B-cell lymphoma
Condition
Cancer
Blood and Immune System
Drug guidance
17 February 2025
Deucravacitinib for moderate-to-severe chronic plaque psoriasis
Condition
Skin
Blood and Immune System
Drug guidance
17 February 2025
Dostarlimab for treating dMMR or MSI-H primary advanced or recurrent endometrial cancer
Condition
Cancer
Gynaecological
Drug guidance
17 February 2025
Durvalumab in combination with tremelimumab for treating unresectable hepatocellular carcinoma
Condition
Cancer
Liver
Drug guidance
17 February 2025
Glofitamab for relapsed or refractory diffuse large B-cell lymphoma after two or more lines of systemic therapy
Condition
Cancer
Blood and Immune System
Drug guidance
17 February 2025
Pembrolizumab for treating locally advanced unresectable or metastatic HER2-positive gastric or gastroesophageal junction adenocarcinoma
Condition
Cancer
Gastrointestinal tract
Drug guidance
17 February 2025
Pembrolizumab for treating resectable Stage II, IIIA, or IIIB (T3-4N2) non-small-cell lung cancer
Condition
Cancer
Respiratory
Drug guidance
17 February 2025
Sacituzumab govitecan for unresectable locally advanced or metastatic HR-positive, HER2-negative breast cancer
Condition
Cancer
Breast
Drug guidance